Methotrexate, vinblastine, epidoxorubicin and cisplatin (M-VEC) in patients with locally advanced transitional bladder cancer

Antonio Frassoldati(Italian Oncology Group of Clinical Research), V. Silingardi(Azienda Ospedaliero-Universitaria di Modena), C. A. Pollastri(University of Modena and Reggio Emilia), P. P. Palladini, G. Berri, Maurizio Brausi(De Agostini (Italy)), Fausto Barbieri(University of Modena and Reggio Emilia), G. Castagnetti(University of Modena and Reggio Emilia), Massimo Federico(University of Modena and Reggio Emilia)

Medical Oncology and Tumor Pharmacotherapy

June 1, 1991

10.1007/bf02988861

Cited by 8

Related Papers

Variability in the Recurrence Rate at First Follow-up Cystoscopy after TUR in Stage Ta T1 Transitional Cell Carcinoma of the Bladder: A Combined Analysis of Seven EORTC Studies

|European Urology|2002|682

EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin

|European Urology|2015|639

Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project

|Blood|2011|431

Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study

|Journal of Clinical Oncology|2012|368

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

|Annals of Oncology|2012|339